Skip to content

Comparing Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism

Comparing Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04404725
Enrollment
64
Registered
2020-05-27
Start date
2020-08-06
Completion date
2021-07-29
Last updated
2022-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Presbyopia

Brief summary

The objective of the study was to compare the handling and performance of Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism.

Detailed description

The objective of the study was to compare the handling and performance of Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism. This is a prospective, randomized, participant masked, crossover, bilateral dispensing study.

Interventions

DEVICEcomfilcon A

Subjects will be randomized to wear comfilcon A for one month.

Subjects will be randomized to wear samfilcon A for one month.

Sponsors

CooperVision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
17 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Is at least 42 years of age and has full legal capacity to volunteer; 2. Has read and signed an information consent letter; 3. Self reports having a full eye examination in the previous two years; 4. Anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week; 5. Is willing and able to follow instructions and maintain the appointment schedule; 6. Habitually wears soft contact lens for the past 3 months minimum; 7. Has refractive astigmatism of at least -0.75DC; 8. Is presbyopic and requires a reading addition of at least +0.75D; 9. Can be fit and achieve binocular distance vision of at least 20/30 Snellen (or +0.20 logMAR) which participants also deem to be 'acceptable', with the available study lens parameters (sphere +4 to -6; cylinder -0.75 to -1.75DC; near addition +0.75 to +2.50).

Exclusion criteria

1. Is participating in any concurrent clinical or research study; 2. Habitually wears one of the study contact lenses; 3. Has any known active\* ocular disease and/or infection; 4. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 5. Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable; 6. Has known sensitivity to the diagnostic sodium fluorescein and/or the care product Opti-Free PureMoist being used in the study; 7. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment; 8. Has undergone refractive error surgery. \* For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Design outcomes

Primary

MeasureTime frameDescription
Ease of Lens Handling at InsertionDay 28Subjective at-home ratings for ease of lens handling for insertion, using a 0-10 scale (0-Very difficult, 10 - Very easy).

Countries

Canada, United States

Participant flow

Pre-assignment details

Of the 64 eligible participants, 63 were dispensed with study products, and one participant withdrew after the screening visit due to lens handling and general time commitment concerns.

Participants by arm

ArmCount
Overall Study
Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study. The baseline measures include information of all 64 eligible participants. Of the 64 eligible participants, 63 were dispensed with study products, and one participant withdrew after the screening visit due to lens handling and general time commitment concerns.
64
Total64

Withdrawals & dropouts

PeriodReasonFG000FG001
First InterventionWithdrawal by Subject02
Second InterventionAdverse Event11
Second InterventionWithdrawal by Subject01

Baseline characteristics

CharacteristicOverall Study
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
64 Participants
Age, Continuous53.9 years
STANDARD_DEVIATION 8.9
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Canada
48 participants
Region of Enrollment
United States
16 participants
Sex: Female, Male
Female
47 Participants
Sex: Female, Male
Male
17 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 610 / 63
other
Total, other adverse events
9 / 619 / 63
serious
Total, serious adverse events
0 / 610 / 63

Outcome results

Primary

Ease of Lens Handling at Insertion

Subjective at-home ratings for ease of lens handling for insertion, using a 0-10 scale (0-Very difficult, 10 - Very easy).

Time frame: Day 28

Population: Out of 58 subjects who completed the study, data of three participants from the comfilcon A Arm /group and data of two participants from samfilcon A Arm / group was excluded from the analysis due to minor protocol deviations.

ArmMeasureValue (MEAN)Dispersion
Comfilcon AEase of Lens Handling at Insertion8.6 score on a scaleStandard Deviation 1.6
Samfilcon AEase of Lens Handling at Insertion8.8 score on a scaleStandard Deviation 1.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026